T01-15 April 20, 2001
Print Media: 301-827-6242
Broadcast Media: 301-827-3434
Consumer Inquiries: 888-INFO-FDA
FDA Warns About Orlaam
The U.S. Food and Drug Administration (FDA) issued a new warning about
health risks associated with levomethadyl acetate HC, a.k.a. Orlaam, a drug
used to treat opiate addiction.
FDA Announces Labeling Changes Following
Cardiac Adverse Events With Addiction Drug
The FDA is strengthening warnings to physicians about serious cardiac adverse events associated with Orlaam (levomethadyl acetate HC), a drug for opiate addiction treatment.
FDA has changed the Orlaam labeling to increase the strength of the warnings and to highlight these warnings in a black box, the most prominent warning on prescription drugs.
In addition, the approved indication for Orlaam will be revised to indicate that the drug is not to be used as first line therapy. Orlaam should be reserved for use in treatment of opiate-addicted patients who fail to show an acceptable response to other adequate treatments for addiction.
As of March 30, 2001, 10 cases of serious arrhythmias have been submitted to FDA through MedWatch — FDAs safety surveillance program. An estimated 33,000 patients have been treated with Orlaam to date.
Roxane Laboratories, Inc., the drugs manufacturer, mailed a Dear Healthcare Professional letter on April 18 to physicians licensed to treat narcotic addiction.
Approved in 1993, Orlaam can be given less often than methadone, which means that patients visit the clinic less frequently and do not need to bring medication home.
At the time of approval there was a signal that the drug may prolong cardiac conduction, and as a result, the labeling included precautions about cardiac adverse events. Since the drugs approval, FDA has received small but increasing numbers of adverse event reports. In addition, European regulatory agencies have also received reports of serious cardiac arrythmias, or deviations of the normal heart rhythm.
ORLAAM is contraindicated in patients with known or suspected arrythmias and any drug known to have the potential to cause abnormal heart rhythm should not be used together with Orlaam.
If a patient taking Orlaam experiences palpitations, dizziness, light-headedness, or seizures, the patient should seek medical attention.
More information about ORLAAM and labeling changes, is available from Roxane Laboratories Technical Product Information at 1-800-962-8364. Cases of adverse events may be reported to 1-800-FDA-0178, or on the internet at www.fda.gov/medwatch.
On Thursday, April 19, 2001, a statement was released by The European Agency for the Evaluation of Medicinal Products – EMEA – which is to be found at the following address http://www.emea.eu.int/
Click on the “Product Alert” button.
This alert it advises MDs “to review their patients [receiving LAAM] immediately. In addition, physicians are advised to switch their patients from Orlaam to another existing alternative, e.g., methadone.”
The recommendations involve “suspending the marketing authorizations of Orlaam.”
Anyone taking LAAM needs to be reevaluated immediately! If there is any way possible, have your treatment provider change your medication to methadone until more is known about the risks involved with using LAAM.